Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 12, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/jpm12081227
Keywords
NSCLC; miRNA; diagnostic marker; prognostic factor; predictive factor; therapy
Ask authors/readers for more resources
Lung cancer, a leading cause of global cancer-related deaths, is often diagnosed at advanced stages due to limited diagnostic possibilities. However, the use of miRNAs as diagnostic, predictive, and prognostic markers in non-small-cell lung cancer (NSCLC) has gained attention in recent years. Abnormal expression levels of miRNAs can detect NSCLC in its early asymptomatic stages, potentially improving clinical outcomes and serving as predictive factors for NSCLC treatment.
Lung cancer remains a leading cause of cancer-related deaths worldwide, overtaking colon, breast, and prostate cancer-related deaths. Due to the limited diagnostic possibilities, it is often diagnosed after it has reached an advanced stage. The delayed diagnosis significantly worsens the patient's prognosis. In recent years, we have observed an increased interest in the use of microRNAs (miRNAs) as diagnostic, predictive, and prognostic markers in non-small-cell lung cancer (NSCLC). The abnormal expression levels of the miRNAs could be used to detect NSCLC in its early stages while it is still asymptomatic. This could drastically improve the clinical outcome. Furthermore, some miRNAs could serve as promising predictive and prognostic factors for NSCLC. Some of the currently available studies have shown a correlation between the miRNAs' levels and the sensitivity of tumour cells to different treatment regimens. Analysing and modulating the miRNAs' expression could be a way to predict and improve the treatment's outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available